The pharmaceutical and the bio-industry involved in developing new medicines is rapidly expanding. This expansion is fueled by the expansion of the new drug candidate material development market using artificial intelligence (AI) and big data; as a result, the clinical trial market is also growing rapidly.
South Korean startup Mediaiplus wants to disrupt the medicine development market by removing bottlenecks that occur at many places before new drug candidates are made. The startup that works as a navigator for clinical trials provides customized clinical trial protocols for its client.
The target client of the startup is those who require curated clinical trials data to launch drug development projects. Using AI, the company aims to revolutionize medicinal research and accentuate the process of new drug formulation for the healthcare sector by ensuring that minimum time is consumed during the formulation of a new drug.
Extensive data that helps make trials faster
Mediaiplus provides the best fitting clinical trials information by showing the result from more than 370,000 cases of clinical trials. The data saves the time of the industry partner and keeps them from getting into the vicious cycle of messy public databases. The startup has developed “MediC” platform through investigator-generated data, deep learning of biology, pharmacology, medicine, and artificial intelligence to optimize clinical trials. Extensively created data is available at a click and the client can type their interests in the search form and have the best matching cases at their disposal. Optimized information is available for the client to search.
Additionally, the startup offers an easy information navigator. One can easily monitor similar clinical trials’ progress status and cover all the latest trends of clinical trial cases. Mediaiplus’ database covers over 400,000 clinical data from all around the world. It provides customized reports for specific areas of interest. The database is updated daily and gives the latest trends. The company can also offer consultation with industry specialists.
Jihee Jung, CEO of Mediaiplus, wants to establish a clinical trial service foundation and later wants to venture into pre-clinical trial service, providing a holistic solution in the field for her company’s client. The company aims to enter the North American market by 2023 to expand its global footprint.
